Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant in ER+/HER2- Metastatic Breast Cancer (ELCIN)
NCT05596409Phase 2Active, not recruiting
- Sponsor
- Stemline Therapeutics
- Start
- May 2023
- Primary completion
- Nov 2026
- Modality
- Molecular Glues
- Countries
- 6
01
Overview
A Phase 2 trial of elacestrant in breast cancer, sponsored by Stemline Therapeutics. Started May 2023; status: active, not recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05596409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05596409.